Showing results (231-240 of 322) with videos related to

Sort By:
Pageof 33
American Journal of Hematology|June 6, 2024
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemiaPaola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
Blood|March 30, 2017
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosisPaola Guglielmelli, Annalisa Pacilli, Giada Rotunno, et al.
Blood|September 17, 2011
EZH2 mutational status predicts poor survival in myelofibrosisPaola Guglielmelli, Flavia Biamonte, Joannah Score, et al.
Blood Advances|November 29, 2023
Functional relevance of circRNA aberrant expression in pediatric acute leukemia with KMT2A::AFF1 fusionCaterina Tretti Parenzan, Anna Dal Molin, Giorgia Longo, et al.
Leukemia|July 22, 2022
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben Mesa, Claire Harrison, Stephen T Oh, et al.
American Journal of Hematology|January 13, 2012
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemiaAlessandra Carobbio, Guido Finazzi, Juergen Thiele, et al.
British Journal of Haematology|April 12, 2013
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapyGuido Finazzi, Alessandro M Vannucchi, Vincenzo Martinelli, et al.
Blood Advances|April 12, 2023
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trialsSrdan Verstovsek, Ruben Mesa, Vikas Gupta, et al.
Leukemia|February 21, 2018
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohortsAyalew Tefferi, Mythri Mudireddy, Francesco Mannelli, et al.
Hemasphere|May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 TrialClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Pageof 33